New study clarifies concerns regarding commonly used anti-nausea drug ondansetron

December 9, 2013, University of Calgary

For the past two years, warnings regarding the possible link between a commonly used anti-nausea and vomiting drug ondansetron and heart arrhythmias have been a source of uncertainty in emergency departments. New research from The Hospital for Sick Children (SickKids) and the University of Calgary's Alberta Children's Hospital Research Institute helps to clarify the actual risk of ondansetron administration and cardiac arrhythmias in both children and adults. The study is published in the December issue of Annals of Emergency Medicine.

In 2011, the Food and Drug Administration notified health-care professionals and of an ongoing safety review and labelling changes for the anti-nausea drug linking its use to the possibility of inducing abnormal and potentially fatal arrhythmias. The warning also implied that doctors needed to rule out conditions that might place patients at risk for developing an abnormal heart rhythm prior to giving patients the drug. Screening all patients for such conditions requires ECG monitoring and blood testing, which are associated with discomfort, delayed care and may lead to additional unnecessary investigations and anxiety. In 2012, the FDA issued an update linking the risk only to the administration of the drug in high doses intravenously. However, there was no change in the universal screening recommendations to all patients before receiving , in any dose or route.

Following the FDA, Health Canada issued a similar communication (October 9, 2012), warning health professionals about the risk of high-dose intravenous ondansetron and recommending that physicians assess patients for risk factors before administering the drug.

Through an in-depth post-marketing analysis which included a systematic review of published literature, the FDA Adverse Events Reporting System and the World Health Organization Individual Safety Case Reports Database, Drs. Yaron Finkelstein and Stephen Freedman explored this association. They did not find any reports of arrhythmia related to the administration of a single oral dose of ondansetron, the most common administration route, employed in over 85 per cent of doses given to children in emergency departments.

"The non-targeted screening recommendations have potential for patient harm on multiple levels, including withholding an effective treatment, delay of care, additional unnecessary procedures and misdiagnoses," says the study's principal investigator, Dr. Yaron Finkelstein, staff physician in Paediatric Emergency Medicine and Clinical Pharmacology and Toxicology and Associate Scientist at SickKids. "Despite more than 22 years of use and hundreds of millions of ondansetron doses administered worldwide, we did not find evidence to support screening of patients without known risk factors before administering a single oral ondansetron dose." Dr. Finkelstein is also an Associate Professor of Paediatrics, Pharmacology and Toxicology at the University of Toronto.

Dr. Stephen Freedman, lead author and physician in Pediatric Emergency Medicine and Gastroenterology at the Alberta Children's Hospital and researcher at the University of Calgary Alberta Children's Hospital Research Institute. "This issue has caused significant uncertainty in the community where single oral dose of ondansetron administration is a routine event. I think these findings add significant clarity to the warnings issues by regulatory authorities and can be employed to support current practice which does not include routine screening to search for high-risk patients." Dr. Stephen Freedman is also an associate professor at the University of Calgary.

The authors concluded that ECG screening and electrolyte testing should be targeted to patients with known such as patients with cardiac diseases or those concomitantly receiving other arrhythmia-inducing medications and those receiving ondansetron intravenously or repeated doses, while it is not warranted in low-risk individuals who are receiving a single oral dose.

Explore further: FDA: Zofran 32-mg dose pulled from market

Related Stories

FDA: Zofran 32-mg dose pulled from market

December 6, 2012
(HealthDay)—The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according to a Drug Safety ...

FDA warns of cardiac risk with stress test agents

November 22, 2013
(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

FDA warning against high dose antidepressant prescription may be unwarranted, study finds

May 3, 2013
The U.S. Food and Drug Administration's warning that high doses of the antidepressant citalopram can cause potentially serious abnormal heart rhythms might be doing more harm than good.

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.